[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.74.94. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
May 10, 1995

Promising New Treatments for Cytomegalovirus Retinitis

Author Affiliations

From the Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (Dr Polis) and the Critical Care Medicine Department, Warren Grant Magnuson Clinical Center (Dr Masur), National Institutes of Health, Bethesda, Md.

JAMA. 1995;273(18):1457-1459. doi:10.1001/jama.1995.03520420073041
Abstract

THE SURVIVAL of patients infected with the human immunodeficiency virus (HIV) has improved over the past decade due to the use of antiretroviral therapy and better management of acquired immunodeficiency syndrome (AIDS)—related opportunistic infections. Some opportunistic infections are declining in incidence due to the use of effective chemoprophylaxis. From the period 1985 to 1987 to the period 1991 to 1992, for example, the incidence of Pneumocystis carinii pneumonia (PCP) as an AIDS-defining illness in the United States declined from 60.9% to 42.5% (written communication, Jonathan Kaplan, MD, Centers for Disease Control and Prevention, Atlanta, Ga, March 1995). However, as patients live longer with very low CD4 counts, it is not surprising that the incidence of other opportunistic infections has increased. Over the same time intervals, the incidence of cytomegalovirus (CMV) retinitis has increased from 2.8% of AIDS-defining illnesses to 5.9%.1Pneumocystis carinii prophylaxis has been responsible for much of

First Page Preview View Large
First page PDF preview
First page PDF preview
×